Flotation still on but problems mount for Sulzer Medica
This article was originally published in Clinica
Shares in Sulzer Medica continue to slide after the company warned of higher numbers of revision surgeries on patients implanted with its hip and knee products. The company also said that it was likely that the related costs would exceed the limits of its insurance coverage, which "could negatively impact earnings". Analysts have estimated that final costs could be as high as SFr1 billion ($560 million).